Who are Vabomere's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xacduro (Copackaged), Avycaz, Zosyn, Unasyn, Augmentin 250.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vaborbactam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Vabomere — Competitive Intelligence Brief

Vabomere (VABORBACTAM) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta Lactamase Inhibitor [EPC]. Area: Infectious Disease.

marketed beta Lactamase Inhibitor [EPC] Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vabomere (VABORBACTAM) — Rempex Pharms Inc. Vabomere works by binding to and inhibiting bacterial beta-lactamase enzymes, allowing other antibiotics to effectively target and kill bacteria.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vabomere TARGET	VABORBACTAM	Rempex Pharms Inc	marketed	beta Lactamase Inhibitor [EPC]		2017-01-01
Xacduro (Copackaged)	DURLOBACTAM	Entasis Therap	marketed	beta Lactamase Inhibitor		2023-01-01
Avycaz	AVIBACTAM	Cerexa Inc	marketed	beta Lactamase Inhibitor [EPC]		2015-01-01
Zosyn	TAZOBACTAM	Merck Sharp & Dohme B.V.	marketed	beta Lactamase Inhibitor		1993-01-01
Unasyn	SULBACTAM	Pfizer	marketed	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	marketed	beta Lactamase Inhibitor		1984-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-12 — Avycaz · 7612087 · US
2028-05-15 — Zosyn · 7129232 · US
2030-10-08 — Avycaz · 8835455 · US
2031-08-08 — Vabomere · 11007206 · US
2031-08-08 — Vabomere · 10172874 · US
2031-08-08 — Vabomere · 10183034 · US
2031-08-08 — Vabomere · 10561675 · US
2031-08-08 — Vabomere · 9694025 · US
2031-08-12 — Avycaz · 8471025 · US
2031-08-29 — Vabomere · 8680136 · US
2032-06-15 — Avycaz · 9695122 · US
2032-06-15 — Avycaz · 8969566 · US
2032-06-15 — Avycaz · 9284314 · US
2032-09-07 — Zosyn · 10028963 · US
2032-09-07 — Zosyn · 9724353 · US
2032-09-27 — Zosyn · 8685957 · US
2032-09-27 — Zosyn · 8476425 · US
2033-04-02 — Xacduro (Copackaged) · 9309245 · US
2033-04-02 — Unasyn · 9309245 · US
2033-04-02 — Xacduro (Copackaged) · 9623014 · US
2033-04-02 — Unasyn · 9623014 · US
2034-03-14 — Zosyn · 8968753 · US
2034-03-14 — Zosyn · 10420841 · US
2034-03-14 — Zosyn · 11278622 · US
2034-03-14 — Zosyn · 9872906 · US
2034-03-14 — Zosyn · 9320740 · US
2034-05-28 — Zosyn · 8906898 · US
2034-09-09 — Zosyn · 10376496 · US
2034-09-09 — Zosyn · 10933053 · US
2035-08-14 — Zosyn · 10125149 · US

Sponsor landscape (beta Lactamase Inhibitor [EPC] class)

Cerexa Inc · 1 drug in this class
Rempex Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vabomere — Competitive Intelligence Brief. https://druglandscape.com/ci/vaborbactam. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab